Skip to main content
. 2019 Dec 23;3(24):4291–4297. doi: 10.1182/bloodadvances.2019001062

Figure 1.

Figure 1.

EFS and OS rates of the 75 PCNSL patients according to risk factors. EFS (A) and OS (B) of the 75 PCNSL patients. (C) EFS of the 56 PCNSL patients without a preexisting disorder vs 14 PCNSL patients with a preexisting disorder. (D) EFS of the 36 PCNSL patients with 1 lesion vs 32 PCNSL patients with ≥2 lesions. (E) EFS of the 68 PCNSL patients who received therapies that included high-dose methotrexate vs 6 PCNSL patients who did not receive high-dose methotrexate. (F) EFS of the 55 PCNSL patients who received therapies with high-dose cytarabine vs 19 PCNSL patients who did not receive high-dose cytarabine.